Bone Marrow Mononuclear Cells (BMMCs)

As The Biospecimen and Biomarker Specialists™, Discovery Life Sciences offers a robust inventory of human Bone Marrow Mononuclear Cells biospecimens for hematology-oncology applications.

For speed, scale, and reliability sourcing BMMCs, choose Discovery.

Optimize Patient Selections For Relevant Study Cohorts With Discovery’s Immunophenotypic Characterization of BMMCs.

Image

CHARACTERIZATIONS OF BMMCS

  • Multiparametric immunophenotyping by flow cytometry tailored to the specific disease indication. For more information see Technical Data Sheets for AML and MM specific panels.
  • HLA Typing: Diseased BMMCs are typed for HLA-A02 via flow cytometry.
  • Patient Demographics: Age, sex, ethnicity, weight, height, smoking status, and alcohol history are available for diseased BMMCs samples.
  • Pathology Report: Confirmation of diagnosis, donor demographic data, date of procedure, and if applicable, current and previous treatments, stage, grade, comorbidities, current medications, and lab values.

Bone Marrow Mononuclear Cells Product Details

Diseased bone marrow mononuclear cells (BMMCs) are composed of both normal and malignant cells and are isolated from bone marrow aspirates using density gradient centrifugation techniques. 

The immunophenotypes of malignant cells are readily identified by flow cytometry and are ready for downstream applications. 

  • BMMCs are frozen in 90% heat-inactivated FBS +10% DMSO and use sodium heparin as an anticoagulant. 
  • Cell counts and viability are determined using AOPI staining on a Nexcelom Cellometer.

BMMC Matched Sets

Our Discovery Partners® network allows for large-scale, prospective collections of high-quality matched sample sets of human biospecimens. 

Each matched sample set is provided with the base clinical data from the patient case, along with redacted pathology information. 

BMMCs Technical Resources

AML BMMC Technical Data Sheet

Product information for acute myeloid leukemia BMMCs characterized by flow cytometry.

 

MM BMMC Technical Data Sheet

Product information for multiple myeloma BMMCs characterized by flow cytometry. 

 

Protocols

Standard processing of diseased bone marrow mononuclear cells (BMMCs).

 

Need Biomarker Characterization For Your BMMCs? 

While our biospecimens are highly characterized, we also provide streamlined multi-omic biomarker analyses to further characterize biospecimens from our inventory or from your studies via our global CLIA / CAP service laboratories*.

Genomic Biomarkers

Image
  • HudsonAlpha Discovery
  • Whole Genome Sequencing
  • Whole Exam Sequencing
  • Targeting Panels
  • Hi-Fi Long Read Sequencing
  • RNASeq
  • Single Cell Sequencing

Tissue Biomarkers

Image
  • IHC
  • Multiplexed IF (mIF)
  • RNA Scope
  • Digital Pathology & Image Analysis
  • PCR
  • In-Situ Hybridization
  • Colorimetric

Cell
Services

Image
  • Flow Cytometry
  • Dissociation & Isolation
  • Cell Culture & Expansion

*HudsonAlpha Discovery Sequencing and Bioinformatics laboratory is CLIA registered, pending CAP accreditation.

Learn More

Frequently Asked Questions

How are BMMCs processed?
  • You can find our protocols by clicking the links below:
  • We also have the ability to follow our clients' custom processing protocols and help them develop new processing protocols based on their needs.
How are the cell counts and viabilities of BMMCs determined?

Cell counts and viability are determined using AOPI staining on a Nexcelom Cellometer.

How is post-thaw cell count and viability performed?
Cryopreserved vials of BMMCs are pulled from vapor phase LN2 freezers, thawed, and assessed on a Nexcelom Cellometer.
What are the recommended storage conditions for the cryopreserved BMMCs?
All live-cell products should be stored in the vapor phase of LN2 until thawed for use.
How are Blast percentages determined?
Discovery BMMCs provide post-thaw blast (CD45lo) and plasma cell (CD138+CD38+) counts via flow cytometry. Additionally, blast percentages are taken from the diagnostic Bone Marrow report obtained from the patient's electronic medical record.

To propel your projects with The Power of Discovery.™

Contact Us Today

Let us know about your project!

Image